Difference between revisions of "Crenolanib (CP-868,596)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 6: | Line 6: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
| − | + | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] | ||
Revision as of 23:13, 28 February 2020
In clinical trials
Preliminary Data
- Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article PubMed